First-Line Steroids: Right Dose, No Add-Ons

First-Line Steroids: Right Dose, No Add-Ons

A 15-minute microlearning activity on matching initial methylprednisolone dosing to GVHD severity (2 mg/kg/d for grade III–IV; 0.5–1 mg/kg/d for limited skin/upper GI disease) and avoiding routine use of alternative or add-on systemic agents in first-line therapy.

Price
Free
Provider
IQ Apparatus
Release date
August 17, 2026
Expires
July 22, 2027
Start activity

Credits

Learning objectives

Upon completion, participants should be able to:

  1. Apply current aGVHD staging, grading, and treatment-response criteria to assess disease severity and identify steroid-refractory disease.
  2. Evaluate clinical and biomarker-based risk-stratification tools to support aGVHD prognostication while recognizing their limitations in guiding routine treatment decisions.
  3. Determine when treatment escalation is appropriate for patients with steroid-refractory aGVHD based on current criteria and guideline recommendations.

Faculty